SC Pharmaceuticals(SZ:002693) Zheng Quan Shi Bao Wang·2025-10-29 14:35Core Viewpoint - *ST Shuangcheng reported significant improvements in its financial performance for the third quarter, driven by the sales of a new product, which has positively impacted its revenue and net profit [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 169 million yuan, representing a year-on-year increase of 33.04% [1] - The net loss attributable to shareholders was 2.52 million yuan, a substantial reduction of approximately 93.33% compared to a net loss of 37.84 million yuan in the same period last year [1] - In the third quarter alone, revenue reached 84.78 million yuan, marking a year-on-year growth of 164.39% [1] - The net profit for the third quarter was 15.94 million yuan, a turnaround from a net loss of 20.89 million yuan in the previous year [1] Cash Flow and Liabilities - The net cash flow from operating activities for the first three quarters was 32.08 million yuan, an increase of 263% year-on-year, attributed to new export product sales and reduced market development expenses [1] - The balance of contract liabilities at the end of the period increased by 31.64% compared to the beginning of the year, mainly due to milestone payments received for product sales rights in the U.S. market [1] Product Development and Market Impact - The revenue growth was primarily driven by the sales of the newly launched product, injectable paclitaxel (albumin-bound), which significantly contributed to the profit increase [1][2] - The company received FDA approval for the ANDA of injectable paclitaxel (albumin-bound) in May, which is a key factor in the substantial performance improvement in the third quarter [3] - The approval indicates that the product meets safety and efficacy standards comparable to the original research level, enhancing the company's international influence and future operational performance [3]